Riskpilot← Back to searchSign inGet full access3P BIOTECH NORWAY AS
ASActiveOrg 992709014Kiland, 3350 PrestfossWholesale of other machinery and equipment · NACE 4664Est. 20080 employeeswww.flowtech.as
Revenue 2024
NOK 0
EBITDA margin
—
-45% vs 2023
Equity ratio
6.3%
Financial strength
Net profit 2024
NOK -53K
-8% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -68K | -45% |
| Net profit | NOK -53K | -8% |
| Total assets | NOK 3,3M | -2% |
| Equity | NOK 206K | -21% |
| Employees | 0 | — |
Legal name
3P BIOTECH NORWAY AS
Org number
992709014
Legal form
Aksjeselskap
NACE code
4664 · Wholesale of other machinery and equipment
Founded
3. juni 2008
Share capital
NOK 165 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder hver for seg.
Company purpose
Produksjon og utvikling av vannrensing-gråvann fra hytter/fritidsboliger og hus, rensing av drikkevann, import og eksport av nærliggende og tilhørende produkter samt deltagelse i andre selskaper.
Address
Kiland, 3350 Prestfoss
Website
www.flowtech.as
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 96 | 73 | 122 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 43 | 2 | −21 | −47 | −68 |
| Depreciation & amort. | −9 | −8 | −3 | −2 | −0 |
| EBIT | 34 | −6 | −24 | −48 | −68 |
| Net financials | −30 | −62 | −21 | −15 | −0 |
| Profit before tax | 5 | −69 | −45 | −63 | −68 |
| Tax | 1 | −15 | −10 | −14 | −15 |
| Net profit | 4 | −54 | −35 | −49 | −53 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 682 | 3 479 | 3 323 | 3 335 | 3 281 |
| Equity | 397 | 343 | 308 | 259 | 206 |
| Long-term debt | 1 801 | 2 584 | 2 637 | 2 833 | 2 855 |
| Short-term debt | 485 | 552 | 379 | 243 | 220 |
| Total debt | 2 285 | 3 136 | 3 015 | 3 076 | 3 075 |
EBITDA margin
-6796800.0%
This company
15.8%
Market median
-43017822% vs market
20202024
Equity ratio
6.3%
This company
38.2%
Market median
-84% vs market
20202024
Return on equity
-25.8%
This company
18.4%
Market median
-240% vs market
20202024
Net profit margin
-5305800.0%
This company
8.1%
Market median
-65503804% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
14.95×
This company
0.62×
Market median
-2311% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KE Chief Executive Officer | Chief Executive Officer | 2013 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fire Invest As
3P BIOTECH NORWAY AS Board members of 3P BIOTECH NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kai Egil Larsen | Chief Executive Officer | 0 companies |
| Terje Midtskogen | Chairman | 0 companies |